Advertisement Proteonomix names new board member - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Proteonomix names new board member

Proteonomix, a biotechnology company, has appointed Steven Byle to its board of directors, effective January 15, 2009.

Mr Byle is presently vice-president of technology for Dockwise, a public, international company, where he is in charge of its R&D program and intellectual property portfolio.

Michael Cohen, CEO of Proteonomix, said: “We welcome Steven to our board of directors. His extensive background both in intellectual property and corporate development shall enhance our company’s growth and development in its commercialization stage.”